RU2373282C2 - ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa - Google Patents

ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa Download PDF

Info

Publication number
RU2373282C2
RU2373282C2 RU2006101391/13A RU2006101391A RU2373282C2 RU 2373282 C2 RU2373282 C2 RU 2373282C2 RU 2006101391/13 A RU2006101391/13 A RU 2006101391/13A RU 2006101391 A RU2006101391 A RU 2006101391A RU 2373282 C2 RU2373282 C2 RU 2373282C2
Authority
RU
Russia
Prior art keywords
polypeptide variant
amino acid
polypeptide
variant according
substitutions
Prior art date
Application number
RU2006101391/13A
Other languages
English (en)
Russian (ru)
Other versions
RU2006101391A (ru
Inventor
Еспер Мортенсен ХААНИНГ (DK)
Еспер Мортенсен ХААНИНГ
Ким Вилбоур АНДЕРСЕН (DK)
Ким Вилбоур АНДЕРСЕН
Клаус БОРНЕС (DK)
Клаус БОРНЕС
Original Assignee
Байер Хелткэр Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Хелткэр Ллк filed Critical Байер Хелткэр Ллк
Publication of RU2006101391A publication Critical patent/RU2006101391A/ru
Application granted granted Critical
Publication of RU2373282C2 publication Critical patent/RU2373282C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
RU2006101391/13A 2003-06-19 2004-06-18 ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa RU2373282C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47978003P 2003-06-19 2003-06-19
US60/479,780 2003-06-19
DKPA200400930 2004-06-15
DKPA200400930 2004-06-15

Publications (2)

Publication Number Publication Date
RU2006101391A RU2006101391A (ru) 2006-06-10
RU2373282C2 true RU2373282C2 (ru) 2009-11-20

Family

ID=33553697

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006101391/13A RU2373282C2 (ru) 2003-06-19 2004-06-18 ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa

Country Status (23)

Country Link
US (5) US20050164932A1 (Direct)
EP (1) EP1644504B8 (Direct)
JP (2) JP4915918B2 (Direct)
KR (1) KR101191779B1 (Direct)
CN (1) CN1839203B (Direct)
AT (1) ATE458057T1 (Direct)
AU (2) AU2004247799B2 (Direct)
BR (1) BRPI0411650A (Direct)
CA (1) CA2529828C (Direct)
CY (1) CY1109984T1 (Direct)
DE (1) DE602004025576D1 (Direct)
DK (1) DK1644504T3 (Direct)
ES (1) ES2338425T3 (Direct)
HR (1) HRP20100264T1 (Direct)
IL (1) IL172364A (Direct)
MX (1) MXPA05013769A (Direct)
NZ (2) NZ573412A (Direct)
PL (1) PL1644504T3 (Direct)
PT (1) PT1644504E (Direct)
RU (1) RU2373282C2 (Direct)
SI (1) SI1644504T1 (Direct)
WO (1) WO2004111242A1 (Direct)
ZA (1) ZA200600539B (Direct)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2705786C2 (ru) * 2013-03-15 2019-11-11 Гладиатор Байосайенсиз, Инк. Gla домены в качестве терапевтических агентов
US11981723B2 (en) 2017-09-05 2024-05-14 GLAdiator Biosciences, Inc. Method of targeting exosomes

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE428445T1 (de) 2000-02-11 2009-05-15 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
DE60334983D1 (de) * 2002-04-30 2010-12-30 Bayer Healthcare Llc Faktor vii oder faktor viia polypeptidvarianten
EP2085470B1 (en) * 2003-03-20 2012-05-16 Bayer HealthCare LLC FVII or FVIIa variants
RU2373282C2 (ru) * 2003-06-19 2009-11-20 Байер Хелткэр Ллк ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa
DK1781782T3 (da) 2004-08-17 2010-08-23 Csl Behring Gmbh Modificerede vitamin K-afhængige polypeptider
EP1893230A2 (en) * 2005-04-26 2008-03-05 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
EP1904528B1 (en) 2005-07-13 2012-10-31 Novo Nordisk Health Care AG Host cell protein knock-out cells for production of therapeutic proteins
PT1907540E (pt) * 2005-07-22 2013-02-04 Bayer Healthcare Llc Activação do factor vii em solução
EP1924689B1 (en) 2005-09-01 2014-08-13 Novo Nordisk Health Care AG Hydrophobic interaction chromatography purification of factor vii polypeptides
WO2007031559A2 (en) 2005-09-14 2007-03-22 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
TW200804416A (en) * 2006-06-19 2008-01-16 Nautilus Technology Llc Modified coagulation factor IX polypeptides and use thereof for treatment
ES2531934T3 (es) 2006-09-01 2015-03-20 Novo Nordisk Health Care Ag Glicoproteínas modificadas
FR2910969B1 (fr) * 2006-12-29 2009-02-27 Lab Francais Du Fractionnement Procede de mesure de la concentration de facteur viia (fviia) dans un echantillon
EP1952822A1 (en) * 2007-01-26 2008-08-06 Novo Nordisk A/S Factor VII polypeptides with increased affinity to platelets
CN101743309B (zh) 2007-04-13 2014-01-29 催化剂生物科学公司 修饰的因子ⅶ多肽及其应用
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
WO2010149172A2 (en) 2009-06-24 2010-12-29 Rigshospitalet SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH.
FR2947181B1 (fr) * 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
SG10201710593UA (en) * 2012-12-24 2018-02-27 Bayer Healthcare Llc Short-acting factor vii polypeptides
CN104211802B (zh) * 2013-05-29 2018-07-27 成都渊源生物科技有限公司 人凝血因子轻链蛋白及其应用
SG11201704706RA (en) 2014-12-10 2017-07-28 Opko Biologics Ltd Methods of producing long acting ctp-modified growth hormone polypeptides
WO2017181145A1 (en) * 2016-04-14 2017-10-19 Iconic Therapeutics, Inc. Compositions and methods for treating disorders associated with νeοvascularization
EP3481855B1 (en) 2016-07-11 2023-09-06 OPKO Biologics Ltd. Long-acting coagulation factor vii and methods of producing same
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2122583C1 (ru) * 1985-04-17 1998-11-27 Займодженетикс Способ получения белка, обладающего опосредованной фактором vii активностью в свертывании крови
WO2000066753A3 (en) * 1999-04-29 2001-04-26 Univ Minnesota Modified vitamin k-dependent polypeptides
WO2001058935A3 (en) * 2000-02-11 2001-11-29 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5180583A (en) * 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
US5258288A (en) * 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S
DK323587D0 (da) 1987-06-25 1987-06-25 Novo Industri As Protein
FI882746A7 (fi) 1987-06-12 1988-12-13 Hoechst Japan Hybridiproteiini C ja menetelmä sen valmistamiseksi.
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
JPH0246296A (ja) 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインｃ及びその製造方法
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5041376A (en) * 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
DE69101634D1 (de) 1990-01-26 1994-05-11 Immuno Ag Wien Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.
EP0521873B1 (en) * 1990-01-29 1999-06-02 Zymogenetics, Inc. Anticoagulant proteins
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5531916A (en) * 1990-10-03 1996-07-02 E. I. Du Pont De Nemours And Company Hydrofluorocarbon cleaning compositions
IE914102A1 (en) * 1990-11-26 1992-06-03 Genetics Inst Expression of pace in host cells and methods of use thereof
HU218890B (hu) 1991-02-28 2000-12-28 Novo Nordisk A/S Véralvadást gátló módosított VII faktorok, ezeket kódoló polinukleotid molekulák, polinukleotid molekulával transzfektált emlős sejtek és a véralvadást gátló módosított VII faktorokat tartalmazó gyógyászati készítmények, valamint a készítmények ...
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
JPH0720127A (ja) * 1993-05-07 1995-01-24 Eisai Co Ltd 各種ｐｉｖｋａの測定方法および測定試薬
ATE210458T1 (de) 1993-05-21 2001-12-15 Zymogenetics Inc Modifizierter faktor vii zur hemmung der vaskulären restenosis und thrombozytenablagerung
DE19531637A1 (de) * 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
US5837843A (en) * 1996-11-08 1998-11-17 Oklahoma Medical Research Foundation Modified protein C
DE69735597T2 (de) * 1996-11-08 2006-12-21 Oklahoma Medical Research Foundation, Oklahoma Verwendung eines modifizierten protein-c
WO1998032466A1 (en) 1997-01-29 1998-07-30 Polymasc Pharmaceuticals Plc Pegylation process
EP1017794A1 (en) 1997-02-06 2000-07-12 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
CA2296770A1 (en) 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
WO1999003498A1 (en) 1997-07-18 1999-01-28 Novo Nordisk A/S USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ADVERSE CONDITIONS RELATED TO THE FVIIa MEDIATED INTRACELLULAR SIGNALLING PATHWAY
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
EP1124946B1 (en) 1998-10-30 2007-06-20 Novozymes A/S Glycosylated proteins having reduced allergenicity
NZ511291A (en) 1998-10-30 2003-08-29 Novozymes As A method for selecting a protein variant that has reduced immunogenicity as compared with the parent or wild-type protein
EP1127154B1 (en) 1998-11-06 2008-09-10 Novo Nordisk Health Care AG Method for the production of fvii
AU3629800A (en) 1999-03-16 2000-10-04 Children's Hospital Of Philadelphia, The Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
US7220837B1 (en) * 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AU2001254624A1 (en) 2000-05-03 2001-11-12 Novo-Nordisk A/S Human coagulation factor vii variants
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
CA2420892A1 (en) * 2000-09-13 2002-03-21 Novo Nordisk A/S Human coagulation factor vii variants
IL154520A0 (en) 2000-09-13 2003-09-17 Novo Nordisk As Human coagulation factor vii variants
AU2001291652B2 (en) 2000-10-02 2007-09-13 Novo Nordisk Health Care Ag Factor VII glycoforms
US7173000B2 (en) 2000-11-09 2007-02-06 The Scripps Research Institute Modified factor VIIa
CA2441580A1 (en) 2001-03-22 2002-10-03 Novo Nordisk Health Care Ag Coagulation factor vii derivatives
ATE532858T1 (de) 2001-09-27 2011-11-15 Novo Nordisk Healthcare Ag Menschliche gerinnungsfaktor-vii-polypeptide
ES2490590T3 (es) 2001-11-02 2014-09-04 Novo Nordisk Health Care Ag Polipéptidos de factor VII de coagulación humana
WO2003055512A1 (en) 2001-12-21 2003-07-10 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
DE60334983D1 (de) * 2002-04-30 2010-12-30 Bayer Healthcare Llc Faktor vii oder faktor viia polypeptidvarianten
DK1549677T3 (da) 2002-09-30 2011-07-18 Bayer Healthcare Llc FVII- eller FVIIa-varianter med forøget koagulationsaktivitet
EP2085470B1 (en) 2003-03-20 2012-05-16 Bayer HealthCare LLC FVII or FVIIa variants
US20060116324A1 (en) * 2003-06-13 2006-06-01 Novo Nordisk Healthcare A/G Novel formulations
RU2373282C2 (ru) 2003-06-19 2009-11-20 Байер Хелткэр Ллк ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2122583C1 (ru) * 1985-04-17 1998-11-27 Займодженетикс Способ получения белка, обладающего опосредованной фактором vii активностью в свертывании крови
WO2000066753A3 (en) * 1999-04-29 2001-04-26 Univ Minnesota Modified vitamin k-dependent polypeptides
WO2001058935A3 (en) * 2000-02-11 2001-11-29 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHAH A.M. et al. Manipulation of the membrane binding site of vitamin K-dependent proteins: enhanced biological function of human factor VII, Proc. Natl. Acad. Sci., USA, 1998, v.95, n.8, p.4229-4234. *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2705786C2 (ru) * 2013-03-15 2019-11-11 Гладиатор Байосайенсиз, Инк. Gla домены в качестве терапевтических агентов
RU2711091C2 (ru) * 2013-03-15 2020-01-15 Гладиатор Байосайенсиз, Инк. Gla домены в качестве нацеливающих агентов
RU2731507C1 (ru) * 2013-03-15 2020-09-03 Гладиатор Байосайенсиз, Инк. Gla домены в качестве нацеливающих агентов
US10894075B2 (en) 2013-03-15 2021-01-19 GLAdiator Biosciences, Inc. Gla domains as targeting agents
US12527836B2 (en) 2013-03-15 2026-01-20 GLAdiator Biosciences, Inc. Gla domains as targeting agents
US11981723B2 (en) 2017-09-05 2024-05-14 GLAdiator Biosciences, Inc. Method of targeting exosomes

Also Published As

Publication number Publication date
HRP20100264T1 (hr) 2010-08-31
PL1644504T3 (pl) 2010-08-31
CY1109984T1 (el) 2014-09-10
JP5580283B2 (ja) 2014-08-27
DK1644504T3 (da) 2010-05-25
US7807638B2 (en) 2010-10-05
EP1644504B8 (en) 2010-06-02
AU2010200793B2 (en) 2013-04-04
US20050164932A1 (en) 2005-07-28
EP1644504A1 (en) 2006-04-12
HK1095357A1 (en) 2007-05-04
US20070117756A1 (en) 2007-05-24
MXPA05013769A (es) 2006-03-08
EP1644504B1 (en) 2010-02-17
ZA200600539B (en) 2006-12-27
AU2010200793A1 (en) 2010-03-25
CN1839203A (zh) 2006-09-27
CA2529828C (en) 2013-01-15
WO2004111242A1 (en) 2004-12-23
US20060240526A1 (en) 2006-10-26
PT1644504E (pt) 2010-03-22
ATE458057T1 (de) 2010-03-15
IL172364A (en) 2014-01-30
AU2004247799B2 (en) 2009-12-03
JP4915918B2 (ja) 2012-04-11
JP2006527982A (ja) 2006-12-14
NZ544728A (en) 2009-04-30
DE602004025576D1 (de) 2010-04-01
CN1839203B (zh) 2011-11-16
CA2529828A1 (en) 2004-12-23
SI1644504T1 (sl) 2010-06-30
KR101191779B1 (ko) 2013-01-14
AU2004247799A1 (en) 2004-12-23
JP2012105650A (ja) 2012-06-07
NZ573412A (en) 2010-09-30
BRPI0411650A (pt) 2006-08-08
RU2006101391A (ru) 2006-06-10
US20060241041A1 (en) 2006-10-26
US20060252128A1 (en) 2006-11-09
US8987202B2 (en) 2015-03-24
KR20060022283A (ko) 2006-03-09
ES2338425T3 (es) 2010-05-07

Similar Documents

Publication Publication Date Title
RU2373282C2 (ru) ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa
AU2003266931B2 (en) FVII or FVIIa variants having increased clotting activity
US9353365B2 (en) Factor VII or VIIa polypeptide variants
AU2004221761B2 (en) FVII or FVIIa variants
AU2014253469A1 (en) FVII or FVIIa variants having increased clotting activity
NZ587580A (en) Factor VII or VIIa Gla domain variants
HK1095357B (en) Factor vii or viia gla domain variants
CA2790689A1 (en) Fvii or fviia variants

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20150619